What is the long-term trend for Nektar Therapeutics's amortization of debt discount premium?

Over 2 years (2023 to 2025), Nektar Therapeutics's amortization of debt discount premium has grown at a -39.1% compound annual growth rate (CAGR), from -$14.86M to -$5.51M.

Nektar Therapeutics NKTR Amortization Of Debt Discount Premium

Amortization Of Debt Discount Premium at other companies

NXP SemiconductorsNXPI

$1M0.0%

Microchip TechnologyMCHP

$7.6M-42.4%

Lumentum Holdings Inc.LITE

$1.1M+37.5%

Devon EnergyDVN

$4M-33.3%

ON SemiconductorON

$2.9M0.0%

Extra Space StorageEXR

$12.56M+11.0%

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.19B+1,531%

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's amortization of debt discount premium.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's amortization of debt discount premium?: Nektar Therapeutics (NKTR) reported amortization of debt discount premium of -$1.66M in Q1 2026.
How has Nektar Therapeutics's amortization of debt discount premium changed year-over-year?: Nektar Therapeutics's amortization of debt discount premium decreased by 25.6% year-over-year, from -$1.32M to -$1.66M.
What is the long-term trend for Nektar Therapeutics's amortization of debt discount premium?: Over 2 years (2023 to 2025), Nektar Therapeutics's amortization of debt discount premium has grown at a -39.1% compound annual growth rate (CAGR), from -$14.86M to -$5.51M.